Answers are grounded in this paper and cite their sources.
Background In non-small cell lung cancer (NSCLC), image-guided biopsy must provide tissue for both diagnosis and biomarker-driven treatment selection. We systematically evaluated molecular adequacy of image-guided biopsy techniques for NSCLC biomarker profiling. Methods PubMed/MEDLINE, Embase, Scopus, Web of Science, CENTRAL, and CDSR were searched from inception to 30 May 2026, supplemented by reference screening and forward citation tracking. Eligible studies reported extractable numerator-denominator data for molecular/genotyping adequacy, NGS/genotyping adequacy, PD-L1 adequacy, diagnostic yield, or procedure-related complications. Random-effects meta -analyses of logit-transformed proportions used restricted maximum-likelihood estimation, with I 2 , τ 2 , and 95% prediction intervals. Results Twenty-six studies were included; 25 contributed to the main quantitative evidence base. The primary analysis included 23 study arms and yielded pooled molecular/genotyping adequacy of 89.5% (95% CI, 84.3–93.2%; I 2 = 91.2%; τ 2 = 1.070), with a 95% prediction interval of 48.4–98.7%. Pooled NGS/genotyping adequacy was 88.4% (95% CI, 80.9–93.1%; I 2 = 91.6%), PD-L1 adequacy 93.9% (95% CI, 91.5–95.6%; I 2 = 62.9%), and diagnostic yield 91.7% (95% CI, 86.3–95.1%). Sensitivity analyses did not materially alter the primary estimate. Conclusions Image-guided biopsy provides high average molecular and biomarker adequacy in NSCLC, but performance varies substantially across clinical, procedural, and laboratory settings. Pooled estimates should be interpreted within study-specific testing denominators and workflows rather than as unconditional probabilities of successful biomarker profiling. Diagnostic success and molecular readiness should be reported as distinct outcomes.
No takes yet. Share an insight, caveat, or question.
Marinelli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: